Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?
Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management
Is Ibandronate + Endocrine Therapy Effective for Breast Cancer?
On April 20, 2022, Sonja B. Vliek from University Medical Center Utrecht published the results of the TEAM-IIB Phase III clinical trial on the efficacy and safety of oral Ibandronate + endocrine therapy as adjuvant treatment in estrogen receptor-positive, postmenopausal breast cancer patients in the Journal of Clinical Oncology.
The TEAM-IIB Phase III clinical trial was a multicenter, randomized, open-label trial that randomized estrogen receptor-positive, postmenopausal breast cancer patients (N = 1116) in a 1:1 ratio into two groups: Ibandronate (50mg once daily) + endocrine therapy (3-year treatment period) and endocrine therapy alone (5-year treatment period). The primary endpoint was disease-free survival.
At a median follow-up of 8.5 years, the results showed that disease-free survival showed no significant difference between the two groups. The disease-free survival rate at 3 years post-randomization was: Ibandronate + endocrine therapy group 94% versus endocrine therapy group 91%. The 5-year disease-free survival rate was: Ibandronate + endocrine therapy group 89% versus endocrine therapy group 86%.
Regarding safety, 17% (N = 97/565) of patients in the Ibandronate + endocrine therapy group discontinued treatment due to adverse events. The most common adverse effect identified was dyspepsia, occurring in Ibandronate + endocrine therapy group 16% versus endocrine therapy group 10%.
Based on TEAM-IIB results, Sonja B. Vliek and colleagues concluded that estrogen receptor-positive, postmenopausal breast cancer patients receiving oral Ibandronate + endocrine therapy as adjuvant treatment showed no significant improvement in disease-free survival and do not recommend this therapy as standard treatment.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.00311
This website uses cookies to understand how you interact with it. By accepting, you agree to our use of cookies. Privacy Policy
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4